Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin-piperaquine for mild/common COVID-19
ChiCTR2000030082Phase 4Suspended
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dihydroartemisinin + piperaquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Time to negative conversion of novel coronavirus nucleic acid and Conversion to severe/critical disease. Started Feb 2020; status: suspended.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030082.